Precigen/$PGEN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Precigen
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.
Ticker
$PGEN
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
143
Website
Precigen Metrics
BasicAdvanced
$463M
-
-$0.56
1.82
-
Price and volume
Market cap
$463M
Beta
1.82
52-week high
$2.17
52-week low
$0.65
Average daily volume
2.6M
Financial strength
Current ratio
3.527
Quick ratio
3.39
Long term debt to equity
29.04
Total debt to equity
35.043
Interest coverage (TTM)
-18,578.20%
Profitability
EBITDA (TTM)
-89.331
Gross margin (TTM)
-1,265.44%
Net profit margin (TTM)
-3,728.87%
Operating margin (TTM)
-2,211.16%
Effective tax rate (TTM)
1.11%
Revenue per employee (TTM)
$30,000
Management effectiveness
Return on assets (TTM)
-44.04%
Return on equity (TTM)
-278.55%
Valuation
Price to revenue (TTM)
104.229
Price to book
-32.96
Price to tangible book (TTM)
-12.41
Price to free cash flow (TTM)
-5.818
Free cash flow yield (TTM)
-17.19%
Free cash flow per share (TTM)
-26.99%
Growth
Revenue change (TTM)
-22.76%
Earnings per share change (TTM)
44.55%
3-year revenue growth (CAGR)
-36.42%
10-year revenue growth (CAGR)
-27.01%
3-year earnings per share growth (CAGR)
5.96%
10-year earnings per share growth (CAGR)
-0.33%
What the Analysts think about Precigen
Analyst ratings (Buy, Hold, Sell) for Precigen stock.
Bulls say / Bears say
Analysts have issued a 'Moderate Buy' rating for Precigen, with an average price target of $7.00, indicating potential upside from current levels. (etfdailynews.com)
Institutional investors, such as Charles Schwab Investment Management Inc., have increased their holdings in Precigen, suggesting confidence in the company's prospects. (defenseworld.net)
Precigen's recent $79.0 million private placement offering is expected to extend its cash runway well into 2026, supporting the anticipated commercial launch of PRGN-2012 in the second half of 2025. (stocktitan.net)
HC Wainwright has lowered its Q1 2025 earnings per share estimates for Precigen, now expecting a loss of ($0.08) per share, down from the previous estimate of ($0.04). (defenseworld.net)
JPMorgan Chase & Co. reduced its holdings in Precigen by 4.4% during the fourth quarter, potentially indicating decreased confidence in the company's performance. (defenseworld.net)
Precigen reported a net loss of $24.0 million ($0.09 per share) in Q3 2024, compared to a net loss of $19.8 million ($0.08 per share) in Q3 2023, reflecting widening losses. (stocktitan.net)
Data summarised monthly by Lightyear AI. Last updated on 11 Jul 2025.
Precigen Financial Performance
Revenues and expenses
Precigen Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Precigen stock?
Precigen (PGEN) has a market cap of $463M as of July 28, 2025.
What is the P/E ratio for Precigen stock?
The price to earnings (P/E) ratio for Precigen (PGEN) stock is 0 as of July 28, 2025.
Does Precigen stock pay dividends?
No, Precigen (PGEN) stock does not pay dividends to its shareholders as of July 28, 2025.
When is the next Precigen dividend payment date?
Precigen (PGEN) stock does not pay dividends to its shareholders.
What is the beta indicator for Precigen?
Precigen (PGEN) has a beta rating of 1.82. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.